Advances in therapy have improved overall survival for patients with HER2-positive metastatic breast cancer, but for those with brain metastases—as much as 50% of that population—the outlook has remained grim.
“We don’t generally see drugs that have a survival advantage in this setting,” said Rita Nanda, MD, an associate professor of medicine and the director of breast oncology at The University of Chicago.
Now a new oral oncology drug may help change that picture.